{"id":"homologous-blood-transfusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Acute hemolytic transfusion reaction"},{"rate":null,"effect":"Febrile non-hemolytic transfusion reaction"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Infection transmission (viral, bacterial, parasitic)"},{"rate":null,"effect":"Iron overload (with chronic transfusion)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a supportive therapeutic intervention that transfers whole blood or blood components from a donor to a recipient to treat acute blood loss, anemia, or coagulation deficiencies. The transfused red blood cells restore oxygen delivery to tissues, while plasma and platelets restore hemostatic capacity. It is a standard clinical procedure rather than a drug with a specific molecular mechanism.","oneSentence":"Homologous blood transfusion replaces lost or deficient blood volume and cellular components to restore oxygen-carrying capacity and hemostatic function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:56.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute blood loss requiring volume and oxygen-carrying capacity restoration"},{"name":"Severe anemia"},{"name":"Coagulation disorders or thrombocytopenia requiring hemostatic support"}]},"trialDetails":[{"nctId":"NCT03548766","phase":"PHASE3","title":"Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2018-09-20","conditions":"Blood Disease, Blood Transfusion, Autologous, Blood Doping","enrollment":12},{"nctId":"NCT01490723","phase":"PHASE2","title":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01","conditions":"Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT02519088","phase":"","title":"A New Approach to a Personalized Patient Blood Management Program (pPBM) in Total Hip Arthroplasty (THA)","status":"COMPLETED","sponsor":"Krankenhaus der Barmherzigen Brüder Trier","startDate":"2015-08","conditions":"Postoperative Anemia","enrollment":477},{"nctId":"NCT00912119","phase":"PHASE1","title":"Amicar Pharmacokinetics of Children Having Craniofacial Surgery","status":"COMPLETED","sponsor":"Paul Stricker","startDate":"2009-05","conditions":"Craniosynostosis","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allogenic Blood Transfusion"],"phase":"phase_3","status":"active","brandName":"Homologous Blood Transfusion","genericName":"Homologous Blood Transfusion","companyName":"Hamad Medical Corporation","companyId":"hamad-medical-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"Homologous blood transfusion replaces lost or deficient blood volume and cellular components to restore oxygen-carrying capacity and hemostatic function. Used for Acute blood loss requiring volume and oxygen-carrying capacity restoration, Severe anemia, Coagulation disorders or thrombocytopenia requiring hemostatic support.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}